A major Wall Street endorsement from multiple analysts recently sent shares of Seagate Technology (NASDAQ: STX) up over 7% in a single session, pushing the stock to a new 52-week high. While any double-digit price target increase is notable, the market’s decisive reaction points to a much .... |
Good MorningWall Street extended its winning streak as major indexes climbed to new highs on broad strength in technology shares. The S&P 500 rose 0.5%, the Dow Jones Industrial Average gained 0.3% and the Nasdaq Composite jumped 0.9%, all setting fresh records. Small-cap stocks also rallied, pushing the Russell 2000 above its 2021 peak. Driving much of today’s surge was a partnership announcement between NVIDIA and Intel, sending NVIDIA higher after it revealed a $5 billion equity investment in its longtime rival as the two plan to co-develop data-center and PC products. International futures reflected the upbeat mood, with Japan’s Nikkei 225 futures trading near multi-year highs.
Fixed-income markets registered notable moves ahead of the Federal Reserve’s anticipated first rate cut, with long-term Treasury yields slipping and mortgage rates dipping to their lowest level since early October. The average 30-year fixed mortgage rate fell to 6.26%, down from 6.35% last week, according to Freddie Mac. Overseas, the Bank of England held its benchmark rate at 4% amid lingering inflation concerns, while commodities saw mixed action: crude oil futures edged lower below $64 a barrel and gold prices retreated as the dollar strengthened slightly.
In corporate news, Uber Eats announced a partnership with drone operator Flytrex to begin U.S. deliveries by year-end, underscoring the growing role of logistics technology in food services. Automakers also made headlines as Toyota and Hyundai issued recalls on more than 1.1 million vehicles over seat-belt and instrument-panel issues, a development that could ripple through auto-supplier stocks. Meanwhile, U.S. homeowners and buyers of electric vehicles and heat pumps are racing to claim expiring federal tax credits before year’s end, setting up a late-season boost in clean-energy and home-improvement demand. Featured: Elon’s big $266,000 per second purchase (Ad) 
| Technology | |
A major Wall Street endorsement from multiple analysts recently sent shares of Seagate Technology (NASDAQ: STX) up over 7% in a single session, pushing the stock to a new 52-week high. While any double-digit price target increase is notable, the market’s decisive reaction points to a much ... Read the Full Story |
| From Our Partners | | Bill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97.
It's a single-page, seven-point filter designed to help traders identify weak setups before placing any options trade. Print it, keep it at your desk, and run it before every trade. The download link expires soon. | | Download your free copy of the Smart Trade Options Checklist now |
| Technology | |
Artificial intelligence (AI) is an all-consuming investment thesis that will last for years, if not decades. For many investors, that means investing in some of the year’s hottest stocks, such as NVIDIA (NASDAQ: NVDA) or Palantir (NASDAQ: PLTR). However, many investors are attracted to compa... Read the Full Story |
| Technology | |
Shares of D-Wave Quantum Inc. (NYSE: QBTS) rallied by an impressive 94% year-to-date, but a closer look reveals that the firm is in danger of losing momentum. When looking at the 12-month trailing return of an astronomical 1,800%, the company's performance over 2025 so far is not quite as notewort... Read the Full Story |
| From Our Partners | | Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 is orchestrating what analyst Porter Stansberry calls a total U.S. money reset, bypassing conventional legal channels under the guise of national security.
The last time America reset its currency - under Nixon in the 1970s - it created an average of 1,300 new millionaires a day for over 50 years. Stansberry has identified three asset categories connected to Trump's initiative that could surge, plus his single top investment move. | | Watch the documentary briefing and find out which side you land on |
| Medical | |
Eli Lilly and Company (NYSE: LLY) has been one of the best-performing stocks outside of the AI-enhanced Magnificent 7 stocks over the past 12 months. The company is the leader in the GLP-1 market, which is transforming the management of type 2 diabetes and the obesity market.
LLY stock is up 10... Read the Full Story |
| Finance | |
The FOMC cut interest rates, but the media response indicated that the cuts were less than expected. However, the headlines focused on next year’s tepid outlook for only 25 basis points of cuts are missing the forest for all the trees. While next year’s outlook is tepid, the forecast f... Read the Full Story |
| From Our Partners | | Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now.
Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen.
Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch. | | Watch how to access the legal backdoor before it closes. |
| Energy | |
Bloom Energy (NYSE: BE) received two price target upgrades from two major Wall Street firms in two weeks, citing very similar rationale. This served as a launch signal, igniting two additional booster rockets on a stock already accelerating toward triple-digit territory.
BE stock recently jumpe... Read the Full Story |
| Technology | |
After the start of a rally in August that captured significant investor attention, shares of Intel Corporation (NASDAQ: INTC) have entered a period of consolidation, establishing a new and higher base in the $25 to $26 range. This sideways trading, however, follows a period of positive fundament... Read the Full Story |
| Technology | |
During the first half of September, tech giant Apple (NASDAQ: AAPL) made multiple key product and software announcements. Of course, the most talked about is its latest iPhone lineup on Sept. 9, followed by a deeper reveal of its Apple Intelligence features on Sept. 15.
Over the past several ye... Read the Full Story |
| Technology | |
Oracle (NYSE: ORCL) will soon reach a trillion-dollar valuation, driven by the impact of AI on business operations.
Once a bulky, cumbersome shackle, data has become a treasure trove for businesses, and Oracle is leading the charge to unlock it.
Its fiscal Q1 results prove its leadership posit... Read the Full Story |
| Consumer Staples | |
General Mills' (NYSE: GIS) stock sell-off, warranted or not, has aligned its market with long-term trends and presents a generational opportunity for investors. At mid-September levels, the stock is trading at historically low valuations and yielding nearly 5%, a fascinating figure given the out... Read the Full Story |
| Friday's Early Bird Stock Of The Day Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California. | Should I Buy Gilead Sciences Stock? GILD Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Gilead Sciences was last updated on Thursday, July 16, 2026 at 6:16 PM.
Gilead Sciences Bull Case -
The company has a strong focus on antiviral therapies, particularly for HIV and viral hepatitis, which are critical areas of medical need and have a consistent demand.
-
Gilead Sciences, Inc. has a solid dividend payout ratio of approximately 44.69%, indicating a commitment to returning value to shareholders through dividends.
-
Recent advancements in oncology and cell therapy have positioned Gilead as a leader in innovative treatments, potentially leading to significant revenue growth.
-
The current stock price is around $80, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
-
Gilead operates a global research and commercial organization, enhancing its ability to penetrate various markets and diversify its revenue streams.
Gilead Sciences Bear Case -
Despite its strong product portfolio, Gilead faces intense competition in the biopharmaceutical industry, which could impact market share and pricing power.
-
Regulatory challenges and the lengthy approval process for new drugs can delay potential revenue from new therapies, affecting overall financial performance.
-
Market volatility and economic uncertainties can lead to fluctuations in stock price, which may deter risk-averse investors.
-
Gilead's reliance on a few key products for a significant portion of its revenue could pose risks if those products face market challenges or patent expirations.
-
Recent trends in healthcare policy and pricing pressures may impact profit margins, making it essential for investors to monitor these developments closely.
| | View Today's Stock Pick |
|
| |
|
|
